CompletedPhase 2

Ranibizumab for Diabetic Traction Retinal Detachment

Brazil19 participantsStarted 2008-12

Plain-language summary

The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in patients with advanced proliferative diabetic retinopathy and traction retinal detachment.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy. Exclusion Criteria: * Massive vitreous hemorrhage preventing from detailed posterior pole examination; * Previous intra-ocular surgery other than cataract surgery * Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin * Prothrombin time, partial thromboplastin time or platelet count without normal limits * History of previous thromboembolic events

What they're measuring

amount of intraoperative intra-ocular bleeding

Timeframe: one week

Trial details

NCT IDNCT01201161

SponsorUniversity of Sao Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-01

View on ClinicalTrials.gov More Diabetic Retinopathy trials